{"id":32044,"date":"2025-04-18T17:39:46","date_gmt":"2025-04-18T09:39:46","guid":{"rendered":"https:\/\/flcube.com\/?p=32044"},"modified":"2025-04-18T17:39:47","modified_gmt":"2025-04-18T09:39:47","slug":"neushen-therapeutics-closes-series-a-funding-for-cns-disorder-drug-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32044","title":{"rendered":"NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development"},"content":{"rendered":"\n

NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed a Series A financing round, raising “tens of millions” of US dollars. The funding was led by Shanghai Healthcare Capital, with participation from existing investor Lapam Capital and Cherami Investment. The proceeds will be directed toward the clinical development of its core programs focused on central nervous system (CNS) disorders.<\/p>\n\n\n\n

Company and Product Pipeline<\/strong>
NeuShen Therapeutics is dedicated to innovative drug research and development for CNS disorders. The company employs dual research platforms, including AAV-based gene therapy and small molecule discovery. Its product pipeline includes NS-041, a selective KCNQ2\/3 channel agonist that has completed Phase I clinical trials for indications such as epilepsy, emotional disorders, and pain. Additionally, NS-136, an M4 muscarinic acetylcholine receptor positive allosteric modulator, targets agitation symptoms associated with dementia, including schizophrenia and Alzheimer’s disease. The pipeline also features multiple projects addressing refractory depression, Alzheimer’s disease, and Parkinson’s disease.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed…<\/p>\n","protected":false},"author":1,"featured_media":32047,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,505],"class_list":["post-32044","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-neushen-therapeutics"],"yoast_head":"\nNeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed a Series A financing round, raising "tens of millions" of US dollars. The funding was led by Shanghai Healthcare Capital, with participation from existing investor Lapam Capital and Cherami Investment. The proceeds will be directed toward the clinical development of its core programs focused on central nervous system (CNS) disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32044\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development\" \/>\n<meta property=\"og:description\" content=\"NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed a Series A financing round, raising "tens of millions" of US dollars. The funding was led by Shanghai Healthcare Capital, with participation from existing investor Lapam Capital and Cherami Investment. The proceeds will be directed toward the clinical development of its core programs focused on central nervous system (CNS) disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32044\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-18T09:39:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-18T09:39:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1813.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32044#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32044\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development\",\"datePublished\":\"2025-04-18T09:39:46+00:00\",\"dateModified\":\"2025-04-18T09:39:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32044\"},\"wordCount\":175,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32044#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1813.webp\",\"keywords\":[\"Finance\",\"NeuShen Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32044#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32044\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32044\",\"name\":\"NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32044#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32044#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1813.webp\",\"datePublished\":\"2025-04-18T09:39:46+00:00\",\"dateModified\":\"2025-04-18T09:39:47+00:00\",\"description\":\"NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed a Series A financing round, raising \\\"tens of millions\\\" of US dollars. The funding was led by Shanghai Healthcare Capital, with participation from existing investor Lapam Capital and Cherami Investment. The proceeds will be directed toward the clinical development of its core programs focused on central nervous system (CNS) disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32044#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32044\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32044#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1813.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1813.webp\",\"width\":1080,\"height\":608,\"caption\":\"NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32044#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development - Insight, China's Pharmaceutical Industry","description":"NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed a Series A financing round, raising \"tens of millions\" of US dollars. The funding was led by Shanghai Healthcare Capital, with participation from existing investor Lapam Capital and Cherami Investment. The proceeds will be directed toward the clinical development of its core programs focused on central nervous system (CNS) disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32044","og_locale":"en_US","og_type":"article","og_title":"NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development","og_description":"NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed a Series A financing round, raising \"tens of millions\" of US dollars. The funding was led by Shanghai Healthcare Capital, with participation from existing investor Lapam Capital and Cherami Investment. The proceeds will be directed toward the clinical development of its core programs focused on central nervous system (CNS) disorders.","og_url":"https:\/\/flcube.com\/?p=32044","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-18T09:39:46+00:00","article_modified_time":"2025-04-18T09:39:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1813.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32044#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32044"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development","datePublished":"2025-04-18T09:39:46+00:00","dateModified":"2025-04-18T09:39:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32044"},"wordCount":175,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32044#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1813.webp","keywords":["Finance","NeuShen Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32044#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32044","url":"https:\/\/flcube.com\/?p=32044","name":"NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32044#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32044#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1813.webp","datePublished":"2025-04-18T09:39:46+00:00","dateModified":"2025-04-18T09:39:47+00:00","description":"NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed a Series A financing round, raising \"tens of millions\" of US dollars. The funding was led by Shanghai Healthcare Capital, with participation from existing investor Lapam Capital and Cherami Investment. The proceeds will be directed toward the clinical development of its core programs focused on central nervous system (CNS) disorders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32044#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32044"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32044#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1813.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1813.webp","width":1080,"height":608,"caption":"NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32044#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1813.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32044"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32044\/revisions"}],"predecessor-version":[{"id":32048,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32044\/revisions\/32048"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32047"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}